I think management have made a very positive change in how they are communicating to the market. They are taking the time to explain the announcements in more detail, in layman's terms so to speak. Something they have not been good at in the past IMO. This is important if we want to open our market exposure wider than just scientists or highly experienced people in the space. More exposure equals more money!
Ann: Imugene doses first combination patient in PD1-Vaxx trial, page-31
-
- There are more pages in this discussion • 85 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.2¢ | 4.9¢ | $531.4K | 10.66M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 3429444 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 149299 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |